Yantai Dongcheng Pharmaceutical GroupLtd Second Quarter 2024 Earnings: EPS: CN¥0.058 (vs CN¥0.16 in 2Q 2023)

Simply Wall St · 09/01 01:51

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥773.5m (down 17% from 2Q 2023).
  • Net income: CN¥47.5m (down 65% from 2Q 2023).
  • Profit margin: 6.1% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: CN¥0.058 (down from CN¥0.16 in 2Q 2023).
earnings-and-revenue-growth
SZSE:002675 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yantai Dongcheng Pharmaceutical GroupLtd Earnings Insights

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 2.0% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Yantai Dongcheng Pharmaceutical GroupLtd.